

By the Numbers: Advarra's Response to COVID-19

IRB and IBC Support

100%

Operation Warp Speed vaccine clinical trials supported by Advarra IRB and IBC

2,500+

COVID-19 research sites overseen by Advarra IRB

429

IRB reviewed COVID-19 protocols

76

IBC reviewed COVID-19 submissions

First COVID-19 protocol submission received

February 11

Free transfer of IRB oversight to keep research moving forward despite pandemic restrictions

> 116 studies

over 500 sites



IRB average
turnaround from
submission to review:
1-2 business days



IBC average
turnaround from
submission to review:
4-5 business days



Reviews conducted for Phase I-IV plus observational data and collection research

Research Administration Support

125 remote audits

conducted across 5 continents

20+

Staff augmentation experts deployed to support organizations, some in response to layoffs & furloughs

179

COVID study calendars built for OnCore CTMS customers

bus.

Average study calendar turnaround time



Free Educational Resources




COVID-related webinars and virtual events which reached 15,000+ research professionals

669 eLearning tool downloads

2 1 COVID-centric blog posts

Ask Advarra

Launched March 16, 2020, **Ask The Experts** was the first free source for direct information on IRB, IBC, and regulatory concerns related to COVID-19 and research.



24 hours

target time from question submission to response

90 percent

questions answered same day as submission

655 and counting questions answered

Coronavirus Guidance

Our Coronavirus Guidance webpages provide timely information and explanations about pandemic-related research changes, regulatory guidance updates, and other critical resources. Popular questions from Ask Advarra are posted to the Coronavirus Guidance so that all may benefit.

20,500+ Research professionals helped

425 Subscribers to weekly email updates

Weekly webpage updates

22 updates of the Coronavirus Guidance page

7,000 email updates sent (approx.)

30 topics covered



FDA	Health Canada	AEMPS	HMA
HHS	OCR	MHRA	NCI
VA	Agency of Medicines	EMA	EC
PRIM&R	Agenzia Italiana del Farmaco	CITI	BBK